Life Sciences Archive » June, 2021

Life Sciences - June, 2021

379 articles

• 3 Highlights From NY Opioid Trial's 2nd Day
• Reps Urge DOJ To Deny Sacklers Releases In Purdue Ch. 11
• Okla. Judge Won't Certify Midcase Appeal In Opioid Bellwether
• After AMG Loss, FTC Can't Get Money Award In False-Ad Suit
• Pension Fund Sues BioPharma Board Over COVID Vax Fiasco
• As Medical Pot Sales Begin, SD Gov. Releases Cops' Policy
• Cancer Patients Can't Use Psilocybin Therapy, DEA Argues
• COVID-19 IP Waiver Supporters Splinter On What To Cover
• Key Opioid Study 'Of Zero Assistance,' Doctor Testifies
• Pot Software Co. Says Contract Suit Counterclaims Too Thin
• Gilstrap Says Patent Suit Was Filed Right On Time
• Carolina Casualty Ordered To Pay $17M Arbitration Award
• Teva Says Intas Unit Seeks Cancer Drug Generic Far Too Soon
• State Courts' Stark Lack Of Diversity Demands Action
• Ropes Assists As Vistria Nabs $2.7B For 4th PE Fund
• Facing 1st Jury, Opioid Attys Turn To Instagram, 'Wizard Of Oz'
• Drug Cos. Share Blame For Opioid Crisis, NY Jury Told
• High Court Limit On Patent Challenges To Spur More Fights
• Tech Giants Say TransUnion Ruling Backs PTAB Review Fight
• Trevena Investors Ink $8.5M Deal Over Painkiller Claims
• Ruling Needed Now On Calif. Pay-For-Delay Law, Court Told
• What COVID-19, Social Issues Mean For Pharma Case Juries
• Bankrupt Purdue Pitches $5.39M Exec Payment Plan
• Fla. Judge Wants More On Fraud Claims In $1B Herbalife Suit
• CD&R Makes Increased £2.8B Bid For UDG Healthcare
• Teva Seeks To Revoke IP For J&J Unit's Schizophrenia Drug
• Justices Narrow Bar On Patent Attacks By Inventors
• Opioids Were Mission Of 'Mercy' For Doctors, Expert Testifies
• Takeda Hit With Antitrust Suit Over IBS Drug Amitiza
• Supreme Court Clears Arthrex Docket With Mixed Rulings
• Pa. Woman Too Late To Add 2nd Product To Pelvic Mesh Suit
• Detroit Will Face Trial In Suit Over Medical Pot Raid
• Pharma Co. Says Contract Fight Can't Be Painted As Fraud
• Vaccinated Attys, Witnesses Can Go Maskless At Calif. IP Trial
• 6 Ways To Guide Applications Under New Patent Classification
• Jury Quick To Find Trader Guilty In Illumina Insider Case
• Justices Won't Weigh In On FCA Whistleblower Standard
• Juul Reaches $40M Deal With NC Over Teen Vape Marketing
• Giuliani Suspension Highlights Ethical Pitfalls For All Lawyers
• 3rd Circ. Asks Pa. Justices To Take Up Device Liability Row
• J&J Strikes $230M Opioid Deal With NY AG, Exits Trial
• Judge Rips 'Misleading' Fee Bid In Echo Of State St. Case
• Novartis Says Genentech Won't Return $210M IP Overpayment
• 3 Pharmacies Cut From NY Opioid Trial, CVS Reaches Deal
• NY Feds Say Trader Sought 'Illegal Edge,' Driven By Greed
• Pharma Co. Sues Insurer For Coverage In Opioid Suits
• Mylan Nabs Partial Win On EpiPen Claims, Still Faces Trial
• Israeli Trader Pleads Guilty In Insider Trading Ring
• B. Braun Pushes For Dismissal In PA Cancer Emissions Cases
• PTAB Won't Hear 2 Daiichi PGRs On Cancer Antibody IP
• Health Hires: Sheppard Mullin, Williams Mullen
• Earlier Suit May Void Gilead Whistleblowers' Kickback Claims
• Hemp Tea Co. Won't Dodge THC Suit On Residency Basis
• Latham, Simpson Thacher Rep Car Wash Co.'s $563M IPO
• NJ Attorneys Urged To Avoid Paying For Client Referrals
• Top Product Liability Cases Of 2021: Midyear Report
• J&J's Appeal Of $29M Talc Verdict Meets Skeptical Judges
• 5 Key Details To Know Before Epic Opioid Trial Starts In NY
• FlatWing Denied Atty Fees In Patent Fight With Pfizer Unit
• WTO Panel Debates EU's Alternative To IP Waiver Proposal
• 11th Circ. Backs Pfizer Unit's Win Over False Ad Suit
• Hemp Trade Group Says Farm Bill Legalized Delta-8-THC
• Deals Rumor Mill: Parexel, Hanon Systems, EssilorLuxottica
• Ford Ruling Affirms Basic Principles Of Personal Jurisdiction
• Otsuka Hits Indian Pharma Co. With IP Suit Over Kidney Drug
• Insider Trading Suspect Spars With Gov't At Illumina Trial​​​​​​​
• Medline Accused Of Trying To Hurt Rival With Disinformation
• Boston Firm Choate Adds Ex-GE Counsel To IP Group
• Goodwin-Led Medical App Doximity Prices $606M IPO
• 4th Circ. Undoes $22M Defamation Verdict Against Biotech Co.
• AstraZeneca Sues Cancer Research Co. Over License Breach
• 9th Circ. Is Wrong On Consumer Fraud Injunctive Relief Issue
• Wis. Opioid Settlement Measure Clears State Legislature
• Tax Court Judge Probes Averaging Pricing In Medtronic Trial
• Ex-Mallinckrodt Rep Loses Sanctions Bid In Acthar Suit
• Biopharma Wins $1 In Del. IP Suit Over Ex-CEO's Wrongdoing
• Women Arguing Far Fewer Patent Appeals For Cos. Than Men
• Calif. Jury Clears CVS In $121M Drug Overcharge Trial
• GSK Unveils Long-Awaited Consumer Health Spinoff Plans
• Where FCA Litigation Stands 5 Years After Escobar
• Anticipating Patent System Change-Ups Under Biden
• Televangelist Bakker To Pay $156K Over COVID Cure Claim
• Rimon Makes Inroads In Delaware With IP Hire
• Judge Backtracks On Juror Vaccine Mandate In Opioid MDL
• To Reduce Prescription Prices, Hold Middlemen Accountable
• Holland & Knight Lures Troutman Pepper Partner To Dallas
• Merchant & Gould Taps Two Partners To Lead Practice Group
• Ex-AstraZeneca Rep Wins $2.4M Verdict On Retaliation Claim
• Calif. Judge Rips Monsanto's Atty In $87M Roundup Appeal
• CVS Drug Buyers Seek $121M As Overcharge Jury Trial Wraps
• Imerys Talc Says New Ch. 11 Acquisition Plan Lowers Risk
• Senate Panel Hears 'Disturbing Reality' On Patent Quality
• In Arthrex, Justices Deal New Blow To Agency Independence
• Rhode Island Senate OKs Legalizing, Taxing Cannabis
• Claims Court Explains Why VA Can't Revisit Contract Transfer
• IHS Urges DC Circ. Not To Revisit Tribal Health Costs Ruling
• Teva Settles Mississippi Drug Price-Fix Claims For $925K
• Abbott, Ex-Worker End COVID-19 Tests TM Suit
• Ex-MiMedx CFO Claims Ignorance In Securities Fraud Suit
• Neutrogena Sued Over Claims Sunscreen Contains Benzene
• 5 Practical Takeaways From High Court Arthrex Ruling
• Navigating Inadvertent Attorney-Client Privilege Waivers
• Fed. Circ. Will Return To In-Person Arguments In August
• How SPACs Should Respond To Increasing Scrutiny
• Coronavirus Regulations: A State-By-State Week In Review
• Calif. Bill Would End Damages Injustice For Dead Plaintiffs
• Vaccine Mandate May Skew Opioid MDL Jury, Pharmacies Say
• Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL
• Ex-FDA Chief Counsel Moves To MoFo To Co-Lead Practice
• Morgan Lewis Bows Out Of Price-Fix Case After Conflict Claim
• DuPont Can't Shake Pension Eligibility ERISA Suit
• Arthrex Ruling Leaves Attys Eyeing USPTO For Guidance
• CVS Didn't Need To Report Drug Discounts To PBM, Jury Told
• Ga. Supplement Seller Admits To Selling Unapproved Steroids
• New Arthrex Powers Put Spotlight On USPTO Director Search
• Crowell & Moring Can't Nix Walgreens' Malpractice Suit
• DOL Seeks Employers' Input On Drug Cost Disclosure Policy
• Court Bars Mo. From Enforcing Residency Rules For Pot Cos.
• IRS' IP Pricing In Medtronic Case Untenable, Witness Says
• Pharma Co. Can't Shake €140M AOP Orphan Award Yet
• Fed. Circ. Won't Eye Amgen Case But Disputes 'Sky Is Falling'
• Judge Blasts 'Breathtaking' Atty Fee Bid In Roundup MDL
• Ex-Univar Exec Fights Claim He Owed Notice About Job Hunt
• Okla. Pot Co. Pushes Back In Seed-To-Sale Tracking Challenge
• Health Cos. Must Prepare For Growing Ransomware Threat
• Entwistle, Wolf Haldenstein Vie To Rep Emergent Investors
• High Court Skips Amgen Unit's Arthrex Arguments In IP Case
• Fenwick-Led Cybersecurity Firm Unveils Plans For $880M IPO
• High Court Declines To Review Amarin's Vascepa Fight
• Health Network Sues For Coverage Of Scientist's $10M Award
• Justices Won't Hear Ax of Medtronic Suit In $112M IP Dispute
• A Practical Metric For Annual Patent Filing Targets: Part 2
• Attorneys Beware: Zoom Depositions Are Likely Inadmissible
• High Court Won't Hear Sham Litigation Exception Case
• Justices Add More Oversight To PTAB In Arthrex Ruling
• HHS Pulls Pharmacy Discount Rule Amid Litigation Barrage
• US Chamber Urges Justices To Review NY Opioid Tax Row
• Canadian Hemp Co. Says Seed Dispute Is In Wrong Court
• Biden Loosens Sanctions For COVID-19 Equipment Shipments
• Meet Biden's HHS Watchdog Pick, Who Stoked Trump's Ire
• Mass. Pot Regulators Hit TILT, Ayr With Nearly $600K In Fines
• Health Hires: Sheppard Mullin, Elanco, Yumanity Therapeutics
• Bard Hit With $3M Verdict In Vein Filter Suit
• J&J Accused Of Seeking 'Secrecy' In Fired Exec's Bias Suit
• 4 Firms Lead Clinical Stage Atai For $3B Valuation In IPO
• GSK Gets Top Court Assist In MDL Victory 'Roadmap'
• Munger Tolles 3 Years Ago Quietly Set Stage For ACA Win
• IP Forecast: Pro Wrestler Preps For Video Game Trial
• Claims Court Won't Let VA Revise Med. Supply Deal Transfer
• Walmart CEO Faces Opioid MDL Grilling Despite Protest
• Ex-Merck Sales Rep Asks 9th Circ. To Revive Kickback Fight
• LegitScript Fights Bid To Move Antitrust Claim To Oregon
• Detroit Pot Licensing Scheme 'Likely Unconstitutional'
• Contract Rights Vs. Patent Invalidity: 2 Key Cases To Watch
• Del. Judge OKs Mallinckrodt Toss Of Ill. City's Ch. 11 Claims
• Cooley-Led Biotech Firm Leads 4 IPOs Totaling $847M
• Sens. Advance BigLaw Picks For Fed. Circ., DOJ Criminal Div.
• Telehealth Must Contend With Compounded Medication Regs
• Cosmetics Trade Group Escapes J&J Asbestos-In-Talc MDL
• HHS Chief Faces Call To Fire FDA Brass After Biogen Approval
• NJ Fed. Court Should Ditch Litigation Funding Disclosure Plan
• Deals Rumor Mill: Didi Chuxing, Azelis, EBay
• ACA Survives Latest Republican Challenge At Supreme Court
• Kirkland, Simpson Steer Danaher's $9.6B Aldevron Buy
• Gilead Ruling Guts Investors' Rights, Calif. Appeals Court Told
• Escobar 5 Years Later: How FCA Earthquake Is Reverberating
• Del. Judge Rejects 'Flawed' HHS Pharmacy Discount Rule
• NJ Justices Revive Ex-Pharma Exec's Racial Slurs Claim
• HHS Secretary Becerra Defends $132B Budget Request
• Examiner With Narrow Scope Approved In Purdue Ch. 11
• NYC Doc Gets Over 4½ Years For Taking Insys Kickbacks
• Insurance Language Lesson From An Opioid Ruling
• Latham-Led AI Startup Leads 3 IPOs Raising $538M Combined
• GSK Denied Restitution In Trade Secrets Theft Case
• 3 Firms Aid On $2B SPAC Deal For Firefighting Chemicals Co.
• Complying With New EU Data Transfer Contractual Obligations
• Trader Pushes Back Against Witness In Illumina Insider Trial
• Law Firm Talent Must Reflect Shifting US Demographics
• Cannabis SPACs Are Piquing Investor Interest
• New York Opioid Trial Delayed Again As Jury Selection Lags
• Greenberg Traurig Adds Faegre Drinker Pharma Litigation Vet
• 3rd Circ. Says Tolling Rule Saves Valeant Investors' Claims
• Covington, MoFo Steer Elanco's $440M Pet Pharma Co. Buy
• Thorny Issues Posed By WTO Vaccine Patent Waiver
• Kodak CEO Ordered To Testify In NY's Insider Trading Probe
• Elizabeth Holmes Can't Probe Jurors On Media Consumption
• Mallinckrodt Ch. 11 Plan Disclosure Challenges Shot Down
• Gilead Wants Whistleblowers' Drug Rx Kickback Suit Killed
• Zimmer Biomet Says Fatal Flaws Doom $3B Del. Cashout Suit
• Drugmakers Can't End Calif. Opioid Trial, Judge Rules
• Watchdog Questions Imerys Talc's Ch. 11 Asset Buy Plans
• Genentech Can't Shake Ex-Worker's 401(k) Fee Suit
• Coronavirus Regulations: A State-By-State Week In Review
• Chancery OKs Trimmed $3.45M Fee In Nutraceutical Sale Suit
• Trader Tells Jury He Got No Illegal Info From Scared CPA
• VA's OIG Says PPE Plans Created Pre-COVID Weren't Utilized
• W.Va. State Opioid Claims Will Be Heard By A Jury
• Centene Settles Ohio, Miss. PBM Claims, Sets Aside $1.1B
• Bio-Rad Points To Worker Pacts In Battling 10X Fed. Circ. Win
• $1.8B Biotech Sale Targeted In 3 Delaware Class Suits
• Peruvian Medical Co. Says German Co. Can't Ditch Virus Suit
• CVS Overcharged Insured Drug Buyers $123.7M, Jury Told
• Glenmark, Teva In No Rush For January 2022 Criminal Trial
• Indiana Doctor's Suit Targets 'Monopolist' IU Health System
• Insulin Makers Blast Patients' 3rd Bid For RICO Claims
• Cooley-Led Customer Software Firm Leads 9 IPO Launches
• RI Senate Panel OKs Legalizing, Taxing Cannabis
• Insulin Pen Buyers Can Name Sanofi's Puerto Rico Unit In Suit
• Biden Keeps Trump's Proposal To Curb March-In Rights
• Mallinckrodt Says Ch. 11 Disclosures Have Enough Info
• Anesthesiology Group Aims To Sink Libel Suit Over Articles
• Patients Get Class Cert In Aetna Disc Surgery Lawsuit
• Justices Won't Review Doc's Conviction For Drug Trial Trades
• Purdue Hits Back At Creditor's Motion For Ch. 11 Examiner
• Judges Should Foster Diversity In MDL Leader Appointments
• Allergan Unit Must Face Bulk Of Namenda Pay-For-Delay Suit
• Mallinckrodt Creditors Question Ch. 11 Drug Sale Process
• Ex-CVS Exec Probed On Drug Prices In Overcharge Trial
• Quest Diagnostics Escapes Amazon Temp Worker's Pot Suit
• Insurer Needn't Help Cover $20M Award From Akorn Meds Suit
• Endo Can't Shake FTC Pay-For-Delay Suit, Judge Told
• Tenn. Appeals Court Won't Halt Endo's $2.4B Opioid Trial
• SEC Says Biotech Co. Tricked Investors Out Of Millions
• FDA's Alzheimer's Drug Approval Deepens Searing Debate
• Meet The Judge Overseeing The 1st Opioid Jury Trial
• Tivity Health Investors Seek Approval Of $7.5M Settlement
• Congress Should Step In To Solve The Opioid Crisis
• Brand Battles: Miracle-Gro Aims To Weed Out 'Gromeo' TM
• Medical Device Cases Show Increased Sunshine Act Scrutiny
• Roche Can't Beat $171M Judgment, Fed. Circ. Told
• Skadden-Led Chinese Recruiting Co. Tops Trio Raising $1.4B
• A Biz Strategy Model To Improve Lateral Atty Hiring Diversity
• Boston Hotel's Virus Policy Only Covered 2 Days, Insurer Says
• 2nd Circ. Rejects FTC Antitrust Case Against 1-800 Contacts
• Insys Seeks Ch. 11 Clawback Of $10M In Ex-CEO's Legal Fees
• UK Litigation Roundup: Here's What You Missed In London
• Calif. Counties Battle Drugmakers' Bid To Nuke Opioid Trial
• 9th Circ. Skeptical Of Researcher's Shot At DEA Pot Rule
• IP Forecast: Amazon To Face A Texas Jury Over Voice IP
• Freezer Co. Hit With $15M Verdict Over Destroyed Embryos
• Pa. Chemical Co. Says Patent Dispute Can't Be Arbitrated
• Judge Slams Calif. For Discovery Violation In Generics MDL
• US To Buy 500M Pfizer Vaccine Doses For Global Donation
• 5th Circ. Won't Revive Sanofi Chemo Hair Loss Suit
• CVS Pricing Practice 'Cheated' Insured Drug Buyers, Jury Told
• 2 Israeli Traders Charged In Global Insider Trading Ring
• Teva Gets Judge To Nix Drug IP Inventorship Correction Order
• Sandoz Will Get To Search Rival CFO's Phone In Antitrust Row
• 5 Steps To Successful Mass Tort Management
• How Legal Profession Can Help LGBTQ Patent Attys Thrive
• 2nd Circ. Weighs Insider Trading Raps Post-Bridgegate
• Monsanto's PCBs Caused Brain Damage, Teachers Tell Jury
• Ill. Court Rules Home Health Co. Took Kickbacks
• Lexicon Investors Urge 5th Circ. To Revive Diabetes Drug Suit
• Elizabeth Holmes' Privilege Loss 'A Cautionary Tale,' Attys Say
• COVID Vaccine IP Waiver Talks Heat Up At The WTO
• Goodwin, Latham Steer $2.8B Drug Discovery SPAC Deal
• ChemoCentryx Hit With Investor Suit Over Drug Trial Claims
• Boston Scientific Promotes Veteran Atty To General Counsel
• What Tax Court's Mylan Legal Fee Ruling Means For IP Suits
• Smaller Firms Need Employee Wellness Programs, Too
• MSP Recovery's Opioid Claims Consolidated With Ohio MDL
• Parkinson's Drug Patent Ax In Del. Helps Mylan Win In Vt.
• MDL Accusing Seed Cos. Of Price-Fixing Is Planted In Mo.
• Glenmark Says Glitch Calls For Supplement To DQ Testimony
• Hours After Getting Patents, Teva Sues Eli Lilly Again
• Wash. Pot Sellers Wary Of State's 'Joints For Jabs' Rules
• Aleut Org. Sues Juul For Unequal Impact On Alaska Natives
• 3rd Circ. Revives Trade Secrets Suit Against Aurobindo
• No Centralization Of Acthar Cases In Delaware Yet, JPML Says
• Pa. Panel OKs Unemployment Claim After Medical Pot Firing
• Tilray Settles Contract Dispute With Fla. Cannabis Grower
• FTC Says High Court Ruling Doesn't Doom Injunction Bid
• Judge Takes Ill. City's Attys To Task For Mallinckrodt Filings
• 'Job Sharing' Plan Not Required Under ADA, 4th Circ. Says
• 2 Firms Seek $3.75M For $17.5M Nutraceutical Suit Deal
• AGs Back Bid To Close Sackler Family's Liability Loophole
• Venable Picks Up Hatch-Waxman Trial Veteran
• Coronavirus Regulations: A State-By-State Week In Review
• China Trade Secret Developments Bring Certainty For US Cos.
• Biden Aims To Jolt Lagging Supply Chains
• Teva Fights To Invalidate Astellas' Urinary Drug Patent
• CBD Cream Seller Seeks Sanctions Over 'Frivolous' IP Claims
• Panel Rules Pfizer Can't Get New MDL Over Cancer Drug IP
• Fed. Circ. Mulls Mixed PTAB Rulings In Teva Antibody IP Fight
• CytoDyn Brass Hyped COVID Drug, Dumped Shares, Suit Says
• Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial
• Artificial Intelligence Startup Leads Wave Of 4 IPO Candidates
• Too Late To Change Hormone Pellet Complaint, Ill. Panel Says
• Justices Won't Hear Challenge To FDA Regulation Of E-Cigs
• Calif. Survival Damages Bill Would Cost Cos., Consumers
• Compliance Considerations For Pharma Co. Testing Programs
• How Ad Disputes Between Cos. Fuel Consumer Class Actions
• Cooley, Skadden Steer $2.1B Deal For Primary Care Provider
• What Semiconductor Shortage Means For Patent Drafting
• Horse-Doper's Light Sentence No 'Bellwether,' Judge Warns
• Clinical Trials Manager Settles SEC Insider Trading Suit
• Ex-Pharma Co. Workers Must Arbitrate Whistleblower Claims
• FDA OKs Biogen Alzheimer's Drug Despite Evidence Issue
• JPML Sends McKinsey Opioid Cases To New MDL
• Monsanto Asks 11th Circ. To Create Roundup Label Precedent
• Biotech Insider Gets 6 Mos. For Trading On Deal Talks
• Feds Attack Ex-Theranos CEO's 45-Page Juror Questionnaire
• Retailers, Generics Makers Want Out Of Zantac MDL
• B. Braun Medical Must Face ERISA Suit Over 401(k) Plan
• Classes Get Cert., Lose State Law Claims In Opana MDL
• NY AG Dodges Removal From Imminent Opioid Trial
• Okla. Medical Pot Rule Challenge Ends Over Pot's Illegality
• Opioid Bellwether Trials Against Pharmacies To Be Bifurcated
• FDA Details Drug Security Essentials In 4 Compliance Guides
• EU Won't Budge On COVID-19 Vaccine IP Waiver
• Cannabis Bill Roundup: Colo. Eyes New Caps On Pot Sales
• Health Hires: Nossaman, JCyte, Gravie, McCarter & English
• Fla. High Court Keeps Tight Grip On Medical Pot Licenses
• Bio-Rad Tries To Keep 10X From Talking Up Pandemic At Trial
• Feds Warn Of Biotech Exec's Next Stock Scam Without Prison
• Unpacking The Latest Trends In Biologics-Related IPRs
• Atty Fees Trimmed By $100K In Bluebird Bio Pay Suit
• Former J&J Exec's Workplace Bias Suit Sent To Mediation
• Stop Networking, Start Relationship Marketing
• When Your 9th Circ. Case Needs California High Court Input
• Hearing Loss Biotech Sued By Investor Over 78% Stock Drop
• Drugmakers Fire Torpedo At 'Centerpiece' Of Calif. Opioid Trial
• Patentees Get Boost With China's Version Of Hatch-Waxman
• Diet Supplements Violated TM With Steroid Link, Jurors Hear
• Drugmakers Urge Fla. Court To Trim Zantac MDL
• 1 Firm Eked Ahead Of Peers Amid Bumpy May IPO Market
• Ex-Theranos CEO Can't Have Atty Privilege Via Boies Schiller
• IP Forecast: Fed. Circ. Set To Drill Into Fracking Patent Fight
• Cherokee Tribe Calls McKinsey 'Ringleader' In Opioid Crisis
• Pot Shop Owner Must Share Profits With Aggrieved Ex-Partner
• Lawmakers Seek Probe Of USPTO Director's Sway Over PTAB
• Medical Pot User's Nixed Job Offer Allowed, Hospital Says
• FTC Can't Seek Restitution From Shkreli Until Congress Acts
• Elizabeth Holmes Wants 'Anecdotal' Evidence Blocked In Trial
• Shifting Trends In Marketing Approvals Of Orphan Drugs
• Firm Settles AG's Claim It Traded Referrals For Yacht Outing
• Health, Green Groups Push FDA To Ban PFAS
• Hearing Aid Implant Maker Mostly Wins At PTAB Against Rival
• Purdue Asks To Extend Opioid Suit Shield To End Of Summer
• McKesson, Fla. Pharmacy Chain Settle $7M Contract Row
• What Attorneys Should Know About Fee Deferral
• Pharmacist Says 8 Years Enough For Lab Outbreak Scandal
• Emergent Faces Investor Suit Over Destroyed COVID Vaccines
• 11th Circ. Won't Lift Stem Cell Clinic Ban
• Ark. Pot Agency Wants Out Of City's Row With Harvest Health
• Contractor Owes No Penalty After Slow Gov't Cost Cap Update
• CVS Judge Slams 'Totally Inappropriate' Trial Instructions
• Anthem Patient Wants 9th Circ. Revival Of Device Denial Suit
• Insurer Dodges Cryotherapy Clinic's Virus Coverage Suit
• Wachtell, Skadden Guide MorphoSys' $1.7B Cancer Co. Buy
• Okla. Fights Challenge To State's Pot Tracking Method
• Predictions On Pandemic's Lasting Impact On Legal Education
• DNA Co. Says Calif. Standards Wrongly Used To Trim Suit
• Sen. Wyden Wants Answers On AbbVie's Int'l Tax Practices
• Fight On Tap Over Firms' $4M Fee Bid In CytoDyn Suit Deal
• Cos. Should Review Insurance Policies For PFAS Coverage
• AbbVie Asks Justices To Hear Sham Litigation Exception Case
• Shkreli Punished For Secret Phone But Can Deny Conspiracy
• Del. Chancery Keeps Alive Suit Over Tilray's PE Insider Deals
• FTC's Illumina-Grail Court Case Dropped Despite Cos.' Protest
• New Lead Atty In Opioid MDL Carries On 'Legacy' Of Hanly
• $30.2M Deal, $9.3M Fee Award Greenlit In Lens Price-Fix MDL
• Sanofi Urges 10th Circ. To Revive EpiPen Antitrust Case
• NY AG Demands Kodak Execs Testify In Insider Trading Probe
• Clarus Wins Ax Of Rival's Testosterone Patent Claims
• Fla. Nursery Urges 11th Circ. To Rule In Pot License Dispute
• VA Wants Suit Paused As It Revisits Deal With Defense Agency
• Jurors To Hear About Whistleblower's Lost Texts, Judge Says
• Global Orgs. Unite For COVID-19 Vaccine Distribution Push
• Gibson Dunn-Led Mesa West Lends $178M For Office Complex
• Cleaning Wholesaler Claims Hand Sanitizer Bait And Switch
• Key Ruling Foils GSK Zofran MDL Ahead Of Bellwether
• Sanofi Rips Fed. Circ. Rehearing Bid In Repatha IP Fight
• Roundup Case Shows State Law Can Top Preemption Defense
• Lawyer Perfectionism Is A Disease We Can Control
• Coronavirus Regulations: A State-By-State Week In Review
• Calif. Doc Can't Force CVS To Fill Opioid Prescriptions
• High Court Won't Hear J&J Challenge To $2.1B Talc Verdict